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Intake of conjugated linoleic acid, fat, and other fatty acids in
relation to postmenopausal breast cancer: the Netherlands Cohort
Study on Diet and Cancer1–3
Laura E Voorrips, Henny AM Brants, Alwine FM Kardinaal, Gerrit J Hiddink, Piet A van den Brandt,
and R Alexandra Goldbohm
ABSTRACT
Background: Conjugated linoleic acid (CLA), which is present
in milk products and meat from ruminants, appears to have anti-
carcinogenic activity against breast cancer in animal and in vitro
experiments. To date, few epidemiologic data are available in
humans.
Objective: This study evaluated the relation between intakes of
CLA and other fatty acids and breast cancer incidence in the
Netherlands Cohort Study.
Design: Intake data derived from a validated 150-item food-
frequency questionnaire were linked to an existing database with
analytic data on specific fatty acids in European foods (the
TRANSFAIR study). With 6.3 y of follow-up and 941 incident
cases of breast cancer, multivariate rate ratios and 95% CIs were
calculated for energy-adjusted intakes of fatty acids and CLA-
containing food groups (eg, butter, cheese, milk, other milk prod-
ucts, and meat).
Results: CLA intake showed a weak, positive relation with breast
cancer incidence (rate ratio for highest compared with lowest
quintile: 1.24, 95% CI: 0.91, 1.69; P for trend = 0.02). Statisti-
cally significant positive associations were found with total trans
fatty acids and (borderline) with saturated fatty acids. Significant
inverse associations were found with monounsaturated and cis
unsaturated fatty acids, whereas total fat and energy intake of
CLA-containing food groups were not related to breast cancer
incidence.
Conclusion: The suggested anticarcinogenic property of
CLA in animal and tissue culture models could not be confirmed
in this epidemiologic study in humans. Am J Clin Nutr
2002;76:873–82.
KEY WORDS Cohort study, breast cancer, intake, fat, fatty
acids, conjugated linoleic acid, trans fatty acids
INTRODUCTION
In the 1970s, breast cancer was associated with fat intake on
the basis of national incidence and mortality rates for breast can-
cer and national per capita fat consumption (1). Since then, many
epidemiologic studies focused on the relation between total fat
intake and breast cancer. From reviews and pooled analyses it can
be concluded that cohort studies present no evidence of a positive
association between total dietary fat intake and breast cancer, but
case-control studies occasionally do so (2–4).
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Few studies that have examined the relation between intake of
fat or fatty acids and the risk of breast cancer have addressed the
role of trans fatty acids (TFAs; 5–9). Dietary TFAs predominantly
derive from industrially hydrogenated vegetable and marine oils
but are also found naturally in dairy and other animal fats. The
major TFA in milk, butter, and beef fat is trans vaccenic acid
(11t-18:1). A specific fatty acid with suggested anticarcinogenic
properties is conjugated linoleic acid (CLA), which also is pri-
marily found in dairy products and meat from ruminants and is
hardly present in vegetable products. The anticarcinogenic and
other properties of CLA were recently reviewed (10, 11). CLA is
a collective term describing a mixture of positional and geomet-
ric conjugated diene isomers formed as intermediates in the bio-
hydrogenation of linoleic acid to trans vaccenic acid or elaidic
acid (9t-18:1) by anaerobic bacteria in the rumen of ruminants.
The double bonds in CLA are conjugated—ie, contiguous—unlike
the double bonds of linoleic acid, which are separated by a meth-
ylene group. The isomer most commonly occurring (> 80%) in
dairy products is 9c,11t-18:2 (12). The anticarcinogenic activity of
CLA has been shown in a wide range of animal models (13, 14)
since 1979, when a lipid fraction of cooked ground beef was
shown to have anticarcinogenic activity (15), and further charac-
terized as a mixture of 4 CLA isomers (16). In vitro studies
showed that physiologic concentrations of CLA inhibit the growth
of human breast cancer cells in a dose-dependent manner (17–19).
Animal experiments showed that CLA inhibits the formation of
breast tumors in rats at dietary concentrations of 0.1–1.0% (by wt)
(20). Concentrations of CLA higher than 1% appeared to have no
additional protective effect (21). The protective action of CLA is
independent of the diet’s total fat content, the type of dietary fat
(saturated or unsaturated) (22), or the concentration of linoleic
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acid in the diet (21). Supplementation of CLA to rats during the
developmental stage of the mammary gland only was found to
confer lifelong protection against breast tumors (20). CLA con-
centrations in breast tissue relate inversely to the rate of forma-
tion of new tumors after the administration of a carcinogen to
adult rats (23). Different CLA concentrations in the diets of mice
(0.1%, 0.3%, or 0.9%) were found to exert specific effects on the
immune system but had no effect on tumor growth and tumor vol-
ume after infusion with metastasizing breast cancer cells (24). Pos-
sibly CLA selectively inhibits the growth of estrogen receptor–
positive breast cancer cells—a relation found in vitro (25).
CLA intake in Germany was estimated at 0.35 g/d for women
and 0.43 g/d for men (12). CLA concentrations in milk and dairy
products vary considerably by a factor of up to 10 in studies in
which large numbers of samples are analyzed. Because CLA con-
centrations are dependent on feed composition and use of supple-
ments, seasonal fluctuations in CLA concentrations are seen. On
average, CLA concentrations in milk and dairy products range
from 0.2 to 1.6 g/100 g fat (12, 26–28).
On the in vivo relation between CLA intake or tissue concen-
trations and risk of human breast cancer, few data have been pub-
lished, from case-control studies only, with contradictory results
(29–32). Within the framework of the Netherlands Cohort Study
on Diet and Cancer (NLCS), we used data on CLA concentrations
and other fatty acids in Dutch food products derived from the
TRANSFAIR study (33). With the use of these data, previous
analyses of total fat and several types of fat and breast cancer inci-
dence (34) were updated and extended with individual fatty acids,
including CLA and the very-long-chain n3 polyunsaturated fatty
acids (fish n3 PUFAs), which also have suggested anticarcino-
genic properties (35).
SUBJECTS AND METHODS
The Netherlands Cohort Study
The NLCS is a prospective cohort study that began in Septem-
ber 1986. The study design was reported in detail elsewhere (36).
In brief, the cohort included 62 573 women aged 55–69 y at the
beginning of the study, originating from 204 municipalities with
computerized population registries. A self-administered mailed
questionnaire on dietary habits, lifestyle, smoking, personal and
family history of cancer, and demographic data was completed at
baseline.
Accumulation of person-time in the cohort has been estimated
by biennial follow-up for vital status information of a subcohort
of 1812 women, randomly selected after baseline exposure meas-
urement. No subcohort members were lost to follow-up. The study
was approved by the Institutional Review Boards of TNO Nutri-
tion and Food Research and of Maastricht University.
Identification of cases of breast cancer
The method of record linkage to obtain information on cancer
incidence was described previously (37). In short, follow-up for
incident cancer was established by computerized record linkage
for the entire cohort with all regional cancer registries in the
Netherlands and with the Dutch national database of pathology
reports. Completeness of cancer follow-up was at least 96% (38).
The food-frequency questionnaire
The dietary section of the questionnaire was a 150-item semi-
quantitative food-frequency questionnaire. The questionnaire
concentrated on the habitual consumption of food and beverages
during the year preceding the start of the study. Among the princi-
pal dietary variables were energy and fat intake. Questionnaire data
were key-entered twice and processed for all incident cases and sub-
cohort members in a manner blinded with respect to case and sub-
cohort status. This was done to minimize observer bias in coding and
interpretation of the data. Main nutrient intakes were calculated with
the use of the Dutch food composition table (39). Intakes of specific
fatty acids were calculated from a separate database derived from
the TRANSFAIR study. This was a market basket study in 14 Euro-
pean countries in each of which a maximum of 100 foods contribut-
ing most to the total fat intake of the country were sampled and ana-
lyzed as methyl esters of the fatty acids present in the foods. All
analyses were performed in one central laboratory. In the database,
total fat included triacylglycerol and other lipids, such as phospho-
lipids and sterols. The percentage of triacylglycerol in total fat is
assumed to be 93% on average, but it varies across food sources (33).
The food-frequency questionnaire was validated against a 9-d diet
record. Pearson correlation coefficients between the dietary record
and the questionnaire varied from 0.40 for vitamin B1 to 0.86 for
alcohol intake, with a median of 0.69. For the exposure variables
under study crude (and energy and sex adjusted) Pearson correlation
coefficients were as follows: energy, 0.74; total fat, 0.72 (0.52); sat-
urated fat, 0.73 (0.58); and polyunsaturated fat, 0.73 (0.75) (40).
Population for analysis
Subjects who reported prevalent cancer at baseline other than
nonmelanoma skin cancer, subjects without microscopically con-
firmed cancer, and subjects with incident in situ carcinoma were
excluded. From the subcohort, prevalent cancer cases other than
nonmelanoma skin cancer were excluded as well. Subjects with
incomplete or inconsistent dietary data were excluded from analy-
ses. Criteria for exclusion were 1) subjects who left blank ≥ 60
(of 150) items in the questionnaire and reported eating < 35
items ≥ 1/mo or 2) subjects who left one or more item blocks
(grouping of items, eg, beverages) blank. More details are given
in a separate report (40). In the first 6.3 y of follow-up (Septem-
ber 1986–December 1992), 941 incident breast cancer cases and
1598 subcohort members were left for analyses.
Data analysis
In the present analysis, exposure variables included intake of total
energy, total fat, animal fat, vegetable fat, total fatty acids, saturated
fatty acids, monounsaturated fatty acids, polyunsaturated fatty acids,
trans unsaturated fatty acids, cis unsaturated fatty acids, and specific
fatty acids including palmitic acid, stearic acid, oleic acid, linoleic
acid, linolenic acid, arachidonic acid, and the fish n3 PUFAs eicos-
apentaenoic acid and docosahexaenoic acid. For CLA, the total of the
9c,11t and 9t,11c isomers is used. The TRANSFAIR data on 18:1
trans-isomers were roughly separated into “predominantly trans
vaccenic acid” and “other 18:1 trans- isomers” based on food sources.
To do so, the 18:1 trans-isomers in fat, meat, or milk from ruminants
have been assumed to be predominantly trans vaccenic acid, whereas
18:1 trans-isomers from other sources were considered to be low in
trans vaccenic acid. Fat intake was adjusted for energy intake (41).
Other exposure variables were intake of CLA-containing food
groups: milk and milk products [categorized as whole milk (and prod-
ucts), semiskim milk (and products), fermented whole milk (and
products), and fermented semiskim milk (and products)], cheese,
fresh meat, and processed meat. Subjects were classified into quintiles
or categories of consumption (g/d), based on the distribution in the
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TABLE 1
Mean energy and energy-adjusted fat intake in breast cancer cases and
female subcohort members in the Netherlands Cohort Study, 1986–19921
Cancer cases Subcohort members
(n = 941) (n = 1598)
Energy (kJ) 7057 ± 1670 7055 ± 1715
Fat (g/d)
Total2 74.0 ± 10.8 74.0 ± 10.5
Animal 53.1 ± 14.8 52.8 ± 14.7
Vegetable 20.9 ± 13.0 21.2 ± 13.6
Fatty acids (g/d)
Total3 68.5 ± 10.3 68.6 ± 10.1
Total saturated 29.5 ± 6.7 29.1 ± 6.2
Total monounsaturated 22.1 ± 4.2 22.3 ± 4.2
Total polyunsaturated 15.4 ± 6.4 15.6 ± 6.3
Total trans unsaturated 2.5 ± 0.9 2.5 ± 0.9
Total cis unsaturated 34.9 ± 7.7 35.4 ± 7.7
Palmitic acid, 16:0 14.7 ± 2.9 14.7 ± 2.8
Stearic acid, 18:0 6.7 ± 1.2 6.6 ± 1.2
Oleic acid, 9c-18:1 16.8 ± 3.5 16.9 ± 3.3
Linoleic acid, 9c,12-18:2 13.5 ± 6.3 13.8 ± 6.2
Conjugated linoleic acid, 0.2 ± 0.1 0.2 ± 0.1 
18:2 (9c,11t or 9t,11c)
trans Vaccenic acid, 11t-18:1 0.8 ± 0.4 0.7 ± 0.4
Other 18:1 trans-isomers, 6t or 9t 1.2 ± 0.8 1.2 ± 0.8
Linolenic acid, 9c,12,15-18:3 1.0 ± 0.4 1.1 ± 0.5
Arachidonic acid, 5c,5,8,11,14-20:4 0.10 ± 0.04 0.10 ± 0.04
Eicosapentaenoic acid, 0.03 ± 0.04 0.03 ± 0.04
5c,8,11,14,17-20:5
Docosahexaenoic acid, 0.07 ± 0.06 0.06 ± 0.07
4c,7,10,13,16,19-22:6
1 x– ± SD.
2 Includes other lipids such as phospholipids.
3 Includes 2% unidentified fatty acids.
subcohort. In general, categories were used instead of quintiles when
a large proportion of subjects were nonusers or when for another rea-
son distributions in approximately equal quintiles led to problems.
Analyses were performed with the case-cohort approach (42): cases
were enumerated for the entire cohort, and the person-years at risk of
the entire cohort were estimated for the subcohort sample.
Rate ratios (RRs) and 95% CIs were computed for quintiles or
categories of intake with the statistical package STATA (43).
Exponentially distributed survival times were assumed in the
follow-up period. Tests for trend in RRs were based on two-sided
likelihood ratio tests. Both age-adjusted and multivariate analy-
ses were conducted. To enable comparison, age-adjusted analyses
were restricted to subjects included in multivariate analyses
(eg, with no missing values on confounders included in the mul-
tivariate model). As in our earlier publication, confounders
adjusted for in the multivariate analyses were age, history of
benign breast disease, maternal breast cancer, breast cancer in one
or more sisters, age at menarche, age at menopause, oral contra-
ceptive use, parity, age at first childbirth, Quetelet index, educa-
tion, alcohol use, current cigarette smoking, total energy intake,
and total energy-adjusted fat intake. The addition of energy-
adjusted fat to the model was performed to study the independent
effect of each individual fatty acid (or fat subgroup) on breast can-
cer incidence by substituting it for any other type of fat (34). To
eliminate the effect of potential undiagnosed disease on fat intake,
analyses were repeated excluding (arbitrarily) those cases that
were diagnosed during the first 2 y of follow-up.
RESULTS
In Table 1 mean intakes of energy and energy-adjusted fat and
fatty acids are presented for breast cancer cases and subcohort
members. Differences in energy and nutrient intakes were very
small, as was the case with intakes of CLA-containing product
groups: milk and milk products, cheese, and fresh or processed
meat (Table 2). Mean intake of CLA was 0.2 g/d, 29% of which
originated from butter, 21% from cheese, and 19% from milk and
milk products (Table 3). Twenty-four percent of CLA came from
meat, particularly beef and ground meat.
TABLE 2
Daily consumption of food groups that contain conjugated linoleic acid in
breast cancer cases and subcohort members in the Netherlands Cohort
Study, 1986–19921
Cancer cases Subcohort members
(n = 941) (n = 1598)
g
Milk and milk products 296 ± 190 296 ± 186
Whole 88 ± 117 89 ± 111
Skim 90 ± 127 88 ± 126
Fermented whole 17 ± 42 19 ± 44
Fermented skim 101 ± 119 100 ± 122
Cheese 23 ± 19 23 ± 19
Fresh meat 93 ± 42 93 ± 40
Beef 26 ± 25 24 ± 21
Pork 34 ± 28 36 ± 29
Processed meat 11 ± 12 11 ± 13
1 x– ± SD.
TABLE 3
Sources of conjugated linoleic acid (CLA) contribution of food groups,
subgroups, and individual food items to total CLA consumption in female
subcohort members in the Netherlands Cohort Study, 1986–1992
Food group Contribution
%
Oils, fats, and sauces 29.6
Butter 29.3
Fresh meat and poultry 23.6
Beef 9.5
Beef steak 2.6
Veal 0.3
Other beef 6.7
Pork 3.6
Ground meat 9.1
Ground beef 5.4
Ground beef and pork 3.7
Chicken, turkey, other poultry 0.8
Other meats 0.6
Cheese 20.8
High-fat 20.0
Low-fat 0.8
Milk and milk products 19.4
Whole 10.4
Skim 5.3
Fermented whole 2.3
Fermented skim 1.4
Processed meat 2.5
Other food groups 4.1
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Age-adjusted and multivariate RRs of breast cancer incidence
were calculated for quintiles of energy and energy-adjusted fat
intake (Table 4). Multivariate adjusted RRs were essentially the
same as age-adjusted risk estimates, except that for monounsatu-
rated fatty acids the multivariate RR was substantially lower than
the age-adjusted RR. In multivariate analyses, no statistically
significant trends were found for associations between breast can-
cer incidence and energy intake, intake of fat, vegetable fat, ani-
mal fat, total fatty acids, and total polyunsaturated fatty acids.
Multivariate RRs for the highest compared with the lowest quin-
tile were between 1.02 and 1.05 for energy intake and for veg-
etable and animal fat. For total fat and total fatty acids, the RRs
were 1.16 (95% CI: 0.87, 1.56) and 1.13 (95% CI: 0.84, 1.52),
respectively. For polyunsaturated fatty acids, the RR was 0.88
(95% CI: 0.65, 1.21).
Higher breast cancer incidence was observed with higher intake
of trans unsaturated fatty acids (multivariate RR for the highest
compared with the lowest quintile: 1.30, 95% CI: 0.93, 1.80; P for
trend = 0.01), and borderline with saturated fatty acids (RR: 1.40,
95% CI: 0.97, 2.03; P for trend = 0.11). Inverse associations were
found for total monounsaturated fatty acids and cis unsaturated
fatty acids (RRs for the highest compared with the lowest quin-
tile: 0.61, 95% CI: 0.38, 0.96; P for trend = 0.001, and 0.79, 95%
CI: 0.54, 1.17; P for trend = 0.04, respectively).
In Table 5, RRs for specific fatty acids are presented. Statisti-
cally significant trends with breast cancer incidence were not
found for most fatty acids. For palmitic acid, stearic acid, linoleic
acid, other 18:1 isomers, arachidonic acid, and the fish n3
PUFAs eicosapentaenoic acid and docosahexaenoic acid, multi-
variate RRs for the highest compared with the lowest quintile were
between 0.89 and 1.01. Statistically significant positive trends
were observed for CLA and trans vaccenic acid (multivariate RR
for the highest compared with the lowest quintile: 1.24, 95% CI:
0.91, 1.69; P for trend = 0.02, and 1.34, 95% CI: 0.98, 1.82; P for
trend = 0.006, respectively). Statistically significant negative
trends were observed for oleic acid and linolenic acid (multivari-
ate RR for the highest compared with the lowest quintile: 0.67,
95% CI: 0.44, 1.03; P for trend = 0.001, and 0.70, 95% CI: 0.51,
0.97; P for trend = 0.006, respectively).
On the basis of multivariate analyses, breast cancer incidence
seemed not to be related to intake of milk and milk products or to
specific subgroups of milk products, based on fat content or fer-
mentation (Table 6). No associations were found for cheese, fresh
meat, beef, or processed meat. A statistically significant positive
trend with butter, the major source of CLA, was only present in
the age-adjusted analysis but was less apparent when multivariate
analysis was used. Intake of pork showed a statistically signifi-
cant negative trend with breast cancer incidence, with a multi-
variate RR for the highest compared with the lowest quintile of
0.80 (95% CI: 0.60, 1.08) and a P for trend of 0.02.
DISCUSSION
The present study has almost twice the number of cases of our
previous publication, issued after 3.3 y of follow-up (34), and con-
clusions drawn then can be grossly confirmed. Again, no relation
was observed between intake of energy, total fat, or polyunsatu-
rated fat and breast cancer incidence. In line with earlier results,
intake of saturated fat showed a slightly positive association with
breast cancer incidence, with a similar RR, but was not significant
in the present analysis. With respect to monounsaturated fat, RRs
for the upper compared with the lower quintile of intake were
slightly lower (0.61 compared with 0.75 in the earlier analysis)
and the trend was now significant. The multivariate RR for
monounsaturated fatty acids was substantially lower than the age-
adjusted RR. The main factor responsible is the adjustment for
energy-adjusted total fat intake. In other words, substituting
monounsaturated fat consumption for any other fat is related to a
decrease in breast cancer incidence.
With the opportunity to link the TRANSFAIR database on fatty
acids (33) to food consumption data and breast cancer incidence
of the NLCS, we were able to study the potential protective effect
of CLA on breast cancer incidence in postmenopausal women.
CLA intakes were slightly lower than those estimated for Ger-
many (based on analysis of CLA in 139 foods) (12) and approxi-
mately equal to the estimated intake in 123 Swedish men (44).
Remarkably, a higher intake of CLA appeared to be associated
with a slight increase in risk of breast cancer. The observed posi-
tive trend is in contrast to experiments in animals and in in vitro
studies, where CLA appears to have protective properties against
breast cancer. Although an important difference is that most ani-
mal studies have been performed with a free fatty acid prepara-
tion containing a mixture of CLA isomers, one study showed that
high-CLA butter fat (with predominantly the 9c,11t isomer pres-
ent in triacylglycerols) has anticarcinogenic properties in rats (45).
It has been suggested that the timing of CLA provision might be
important (46). In rats, adding CLA to the diet from the early post-
weaning to the pubertal period only (corresponding to active mor-
phologic development of the mammary gland to the mature state)
was sufficient to reduce subsequent induced tumorigenesis later
in life. When CLA was not present in the diet in this period, but
only after induction of tumorigenesis, inhibition of tumorigenesis
was only maximal if CLA was added continuously afterward (46).
Because the NLCS deals only with data on postmenopausal
women, no data are available on CLA intake in the prepubertal
period, though this might be a more important determinant of later
tumor development (46).
A positive trend similar to that for CLA was found for trans
vaccenic acid, but because intakes of both fatty acids are highly
correlated (Pearson correlation coefficient = 0.95), their effects
cannot be separated.
The major sources of CLA in the human diet—milk and milk
products and meat from ruminants—showed no relation with
breast cancer incidence. Two other longitudinal studies found no
relation with milk consumption either (47, 48), but other prospec-
tive studies have reported inverse (49–51) or positive (52) associ-
ations. In a meta-analysis of cohort and case-control studies, high
consumption of milk and cheese was associated with a very small
increase in breast cancer risk (53). In a recent review, 3 case-control
studies reported a negative association, 5 showed no association,
and 5 a positive association between milk intake and breast can-
cer (54). Other studies found that lower risk of breast cancer was
associated with higher intakes of whole milk but not of low-fat
milk (55). As the World Cancer Research Fund summarized in its
report in 1997 (2), data on the relation between meat intake and
breast cancer incidence are inconclusive, with 3 of 8 cohort stud-
ies reporting a positive association and the remaining 5 reporting
no association [including our previous paper (34)].
The effect of CLA on human breast cancer may be modified by
other dietary factors, such as fiber, leaving the possibility that
CLA may have different effects when it is part of different food
patterns. In general, results should be considered as a contribution
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TABLE 4
Rate ratios (RRs) and 95% CIs for breast cancer according to quintiles (Q) of intake of energy and energy-adjusted fat in the Netherlands Cohort Study,
1986–1992
Exposure Q11 Q2 Q3 Q4 Q5 P for trend
Energy intake
Median intake in subcohort (kJ/d) 5079 6072 6900 7782 9247
No. of cases 139 152 183 158 151
RR2 (95% CI) 1.00 1.09 (0.82, 1.45) 1.34 (1.02, 1.77) 1.13 (0.85, 1.51) 1.04 (0.78, 1.38) 0.68
RR3 (95% CI) 1.00 1.05 (0.78, 1.43) 1.28 (0.95, 1.72) 1.13 (0.84, 1.53) 1.04 (0.77, 1.40) 0.61
Total fat
Median intake in subcohort (g/d) 61 69 74 79 86
No. of cases 166 145 162 143 180
RR2 (95% CI) 1.00 0.83 (0.65, 1.08) 0.95 (0.74, 1.22) 0.84 (0.65, 1.08) 1.05 (0.82, 1.34) 0.66
RR4 (95% CI) 1.00 0.97 (0.71, 1.31) 1.11 (0.83, 1.50) 0.96 (0.71, 1.30) 1.16 (0.87, 1.56) 0.23
Vegetable fat
Median intake in subcohort (g/d) 5 13 21 28 38
No. of cases 161 162 156 148 156
RR2 (95% CI) 1.00 0.93 (0.71, 1.22) 0.96 (0.72, 1.26) 0.87 (0.66, 1.15) 1.01 (0.76, 1.34) 0.83
RR4 (95% CI) 1.00 0.96 (0.71, 1.31) 0.98 (0.73, 1.33) 0.88 (0.65, 1.20) 1.02 (0.75, 1.38) 0.85
Animal fat
Median intake in subcohort (g/d) 35 45 52 60 71
No. of cases 168 155 149 139 172
RR2 (95% CI) 1.00 0.94 (0.71, 1.24) 0.88 (0.69, 1.16) 0.82 (0.62, 1.09) 1.01 (0.77, 1.33) 0.71
RR4 (95% CI) 1.00 0.90 (0.67, 1.22) 0.91 (0.67, 1.24) 0.78 (0.58, 1.06) 1.05 (0.79, 1.40) 0.87
Total fatty acids
Median intake in subcohort (g/d) 56 64 69 73 80
No. of cases 154 147 163 151 168
RR2 (95% CI) 1.00 0.96 (0.73, 1.28) 1.11 (0.84, 1.46) 1.00 (0.76, 1.34) 1.08 (0.82, 1.43) 0.55
RR4 (95% CI) 1.00 1.04 (0.77, 1.41) 1.18 (0.88, 1.60) 1.07 (0.79, 1.45) 1.13 (0.84, 1.52) 0.29
Saturated fatty acids
Median intake in subcohort (g/d) 22 26 29 32 38
No. of cases 140 161 152 142 188
RR2 (95% CI) 1.00 1.14 (0.86, 1.51) 1.07 (0.80, 1.42) 1.01 (0.76, 1.35) 1.31 (0.99, 1.72) 0.08
RR5 (95% CI) 1.00 1.17 (0.86, 1.60) 1.12 (0.81, 1.56) 1.02 (0.72, 1.46) 1.40 (0.97, 2.03) 0.11
Total monounsaturated fatty acids
Median intake in subcohort (g/d) 18 20 22 24 27
No. of cases 168 169 164 142 140
RR2 (95% CI) 1.00 1.02 (0.78, 1.34) 0.97 (0.74, 1.28) 0.84 (0.63, 1.11) 0.89 (0.65, 1.15) 0.06
RR5 (95% CI) 1.00 0.91 (0.66, 1.25) 0.82 (0.59, 1.15) 0.66 (0.45, 0.98) 0.61 (0.38, 0.96) 0.001
Total polyunsaturated fatty acids
Median intake in subcohort (g/d) 8 12 15 18 24
No. of cases 194 136 152 135 166
RR2 (95% CI) 1.00 0.65 (0.50, 0.86) 0.77 (0.59, 1.02) 0.72 (0.54, 0.95) 0.88 (0.67, 1.15) 0.40
RR5 (95% CI) 1.00 0.70 (0.52, 0.95) 0.85 (0.63, 1.15) 0.73 (0.53, 1.00) 0.88 (0.65, 1.21) 0.39
trans Unsaturated fatty acids
Median intake in subcohort (g/d) 1.5 2.1 2.4 2.8 3.6
No. of cases 145 149 153 169 167
RR2 (95% CI) 1.00 1.00 (0.75, 1.33) 1.06 (0.80, 1.41) 1.17 (0.89, 1.55) 1.20 (0.90, 1.58) 0.04
RR5 (95% CI) 1.00 0.98 (0.72, 1.33) 1.09 (0.80, 1.49) 1.20 (0.88, 1.64) 1.30 (0.93, 1.80) 0.01
cis Unsaturated fatty acids
Median intake in subcohort (g/d) 26 31 35 39 45
No. of cases 167 178 150 144 144
RR2 (95% CI) 1.00 1.03 (0.79, 1.35) 0.92 (0.70, 1.22) 0.89 (0.67, 1.18) 0.90 (0.68, 1.20) 0.16
RR3 (95% CI) 1.00 1.10 (0.81, 1.49) 0.92 (0.66, 1.29) 0.89 (0.63, 1.26) 0.79 (0.54, 1.17) 0.04
1 Reference category.
2 Adjusted for age.
3 Adjusted for age, history of benign breast disease, maternal breast cancer, breast cancer in one or more sisters, age at menarche, age at menopause, oral
contraceptive use, parity, age at first childbirth, Quetelet index, education, alcohol use, and current cigarette smoking.
4 Adjusted for age, history of benign breast disease, maternal breast cancer, breast cancer in one or more sisters, age at menarche, age at menopause, oral
contraceptive use, parity, age at first childbirth, Quetelet index, education, alcohol use, current cigarette smoking, and total energy intake.
5 Adjusted for age, history of benign breast disease, maternal breast cancer, breast cancer in one or more sisters, age at menarche, age at menopause, oral
contraceptive use, parity, age at first childbirth, Quetelet index, education, alcohol use, current cigarette smoking, total energy intake, and total energy-
adjusted fat intake.
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TABLE 5
Rate ratios (RRs) and 95% CIs for breast cancer according to quintiles (Q) of intake of specific energy-adjusted fatty acids in the Netherlands Cohort
Study, 1986–1992
Exposure Q11 Q2 Q3 Q4 Q5 P for trend
Palmitic acid
Median intake in subcohort (g/d) 11 13 15 16 18
No. of cases 149 152 169 153 160
RR2 (95% CI) 1.00 0.98 (0.74, 1.31) 1.15 (0.87, 1.53) 1.03 (0.78, 1.37) 1.04 (0.78, 1.37) 0.63
RR3 (95% CI) 1.00 1.00 (0.72, 1.35) 1.14 (0.83, 1.57) 1.00 (0.71, 1.42) 1.01 (0.68, 1.52) 0.89
Stearic acid
Median intake in subcohort (g/d) 5.2 6.0 6.6 7.2 8.0
No. of cases 145 153 172 157 156
RR2 (95% CI) 1.00 1.06 (0.80, 1.41) 1.18 (0.90, 1.56) 1.10 (0.83, 1.46) 1.04 (0.79, 1.38) 0.66
RR3 (95% CI) 1.00 1.04 (0.76, 1.43) 1.13 (0.81, 1.57) 1.02 (0.71, 1.47) 0.93 (0.61, 1.41) 0.65
Oleic acid
Median intake in subcohort (g/d) 13 15 17 18 21
No. of cases 159 188 152 144 140
RR2 (95% CI) 1.00 1.19 (0.91, 1.56) 0.97 (0.73, 1.28) 0.88 (0.67, 1.17) 0.92 (0.69, 1.22) 0.06
RR3 (95% CI) 1.00 1.09 (0.80, 1.49) 0.85 (0.60, 1.20) 0.71 (0.49, 1.05) 0.67 (0.44, 1.03) 0.001
Linoleic acid
Median intake in subcohort (g/d) 7 10 13 16 22
No. of cases 179 149 150 138 167
RR2 (95% CI) 1.00 0.77 (0.58, 1.01) 0.84 (0.63, 1.11) 0.77 (0.58, 1.02) 0.95 (0.72, 1.24) 0.68
RR3 (95% CI) 1.00 0.84 (0.62, 1.14) 0.92 (1.68, 1.24) 0.80 (0.58, 1.10) 0.96 (0.71, 1.31) 0.67
Conjugated linoleic acid
Median intake in subcohort (g/d) 0.07 0.11 0.14 0.19 0.29
No. of cases 127 149 156 175 176
RR2 (95% CI) 1.00 1.13 (0.85, 1.51) 1.19 (0.89, 1.59) 1.31 (0.98, 1.74) 1.34 (1.01, 1.79) 0.005
RR3 (95% CI) 1.00 1.09 (0.79, 1.49) 1.14 (0.83, 1.57) 1.29 (0.95, 1.76) 1.24 (0.91, 1.69) 0.02
trans Vaccenic acid
Median intake in subcohort (g/d) 0.3 0.5 0.7 0.9 1.2
No. of cases 124 155 147 179 178
RR2 (95% CI) 1.00 1.19 (0.89, 1.59) 1.17 (0.87, 1.57) 1.35 (1.01, 1.79) 1.40 (1.05, 1.86) 0.002
RR3 (95% CI) 1.00 1.16 (0.84, 1.59) 1.19 (0.87, 1.62) 1.36 (1.00, 1.85) 1.34 (0.98, 1.82) 0.006
Other 18:1 isomers
Median intake in subcohort (g/d) 0.4 0.8 1.1 1.5 2.3
No. of cases 180 134 164 160 145
RR2 (95% CI) 1.00 0.75 (0.56, 0.99) 0.90 (0.69, 1.18) 0.93 (0.71, 1.22) 0.83 (0.63, 1.09) 0.44
RR3 (95% CI) 1.00 0.80 (0.59, 1.09) 1.01 (0.75, 1.38) 1.01 (0.74, 1.37) 0.89 (0.65, 1.21) 0.91
Linolenic acid
Median intake in subcohort (g/d) 0.6 0.8 1.0 1.3 1.7
No. of cases 194 145 187 133 124
RR2 (95% CI) 1.00 0.76 (0.58, 1.00) 0.92 (0.71, 1.20) 0.69 (0.52, 0.91) 0.68 (0.51, 0.91) 0.001
RR3 (95% CI) 1.00 0.78 (0.57, 1.05) 1.03 (0.76, 1.39) 0.74 (0.54, 1.00) 0.70 (0.51, 0.97) 0.006
Arachidonic acid
Median intake in subcohort (g/d) 0.05 0.07 0.09 0.11 0.15
No. of cases 168 153 147 152 163
RR2 (95% CI) 1.00 0.85 (0.64, 1.12) 0.90 (0.68, 1.19) 0.88 (0.67, 1.16) 1.01 (0.77, 1.33) 0.84
RR3 (95% CI) 1.00 0.80 (0.59, 1.07) 0.84 (0.63, 1.13) 0.80 (0.59, 1.08) 0.99 (0.73, 1.34) 0.93
Eicosapentaenoic acid
Median intake in subcohort (g/d) 0.00 0.01 0.02 0.04 0.08
No. of cases 152 145 170 172 144
RR2 (95% CI) 1.00 1.18 (0.88, 1.56) 1.14 (0.87, 1.50) 1.23 (0.93, 1.62) 1.03 (0.78, 1.37) 0.63
RR3 (95% CI) 1.00 1.15 (0.84, 1.58) 1.10 (0.82, 1.49) 1.22 (0.90, 1.65) 0.98 (0.72, 1.35) 0.87
Docosahexaenoic acid
Median intake in subcohort (g/d) 0.01 0.03 0.05 0.08 0.14
No. of cases 147 156 158 176 146
RR2 (95% CI) 1.00 1.11 (0.83, 1.47) 1.04 (0.78, 1.37) 1.20 (0.91, 1.58) 1.02 (0.77, 1.36) 0.62
RR3 (95% CI) 1.00 1.10 (0.81, 1.51) 1.03 (0.76, 1.40) 1.21 (0.90, 1.64) 1.00 (0.72, 1.37) 0.70
1 Reference category.
2 Adjusted for age.
3 Adjusted for age, history of benign breast disease, maternal breast cancer, breast cancer in one or more sisters, age at menarche, age at menopause, oral
contraceptive use, parity, age at first childbirth, Quetelet index, education, alcohol use, current cigarette smoking, total energy intake, and total energy-
adjusted fat intake.
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TABLE 6
Rate ratios (RRs) and 95% CIs for breast cancer according to quintiles (Q) and categories of intake of milk products and meat in the Netherlands Cohort
Study, 1986–1992
Exposure Q1,C11 Q2,C2 Q3,C3 Q4,C4 Q5 P for trend
Milk and milk products
Median intake in subcohort (g/d)2 72 185 277 367 532
No. of cases 170 148 165 142 158
RR3 (95% CI) 1.00 0.87 (0.66, 1.15) 0.91 (0.69, 1.19) 0.79 (0.60, 1.05) 0.93 (0.70, 1.22) 0.32
RR4 (95% CI) 1.00 0.89 (0.66, 1.19) 0.87 (0.65, 1.17) 0.82 (0.60, 1.11) 0.91 (0.67, 1.24) 0.32
Whole milk and products
Median intake in subcohort (g/d)2 0 21 53 107 232
No. of cases 172 187 143 133 148
RR3 (95% CI) 1.00 1.07 (0.82, 1.39) 0.97 (0.73, 1.29) 0.83 (0.63, 1.10) 0.87 (0.66, 1.15) 0.04
RR4 (95% CI) 1.00 1.10 (0.83, 1.47) 1.00 (0.73, 1.36) 0.88 (0.64, 1.21) 0.90 (0.66, 1.22) 0.12
Skim milk and products
Median intake in subcohort (g/d)2 0 48 203
No. of cases 350 187 246
RR3 (95% CI) 1.00 0.82 (0.66, 1.02) 1.01 (0.82, 1.24) 0.90
RR4 (95% CI) 1.00 0.81 (0.64, 1.02) 1.04 (0.84, 1.30) 0.83
Fermented whole milk and products
Median intake in subcohort (g/d)2 0 53
No. of cases 587 196
RR3 (95% CI) 1.00 0.85 (0.70, 1.04) 0.05
RR4 (95% CI) 1.00 0.88 (0.71, 1.10) 0.15
Fermented skim milk and products
Median intake in subcohort (g/d)2 0 32 172
No. of cases 200 272 311
RR3 (95% CI) 1.00 0.99 (0.78, 1.24) 0.98 (0.79, 1.23) 0.85
RR4 (95% CI) 1.00 0.95 (0.74, 1.21) 0.89 (0.70, 1.14) 0.22
Cheese
Median intake in subcohort (g/d)2 2 13 19 26 90
No. of cases 181 121 167 196 118
RR3 (95% CI) 1.00 0.84 (0.63, 1.13) 0.90 (0.69, 1.17) 0.96 (0.74, 1.24) 1.00 (0.74, 1.34) 0.81
RR4 (95% CI) 1.00 0.81 (0.60, 1.10) 0.88 (0.66, 1.17) 0.91 (0.69, 1.20) 0.94 (0.67, 1.31) 0.78
Butter
Median intake in subcohort (g/d)2 0 13 31
No. of cases 482 158 143
RR3 (95% CI) 1.00 1.14 (0.91, 1.43) 1.24 (0.97, 1.58) 0.02
RR4 (95% CI) 1.00 1.11 (0.90, 1.54) 1.18 (0.90, 1.54) 0.08
Fresh meat
Median intake in subcohort (g/d)2 45 73 91 107 145
No. of cases 168 154 151 156 154
RR3 (95% CI) 1.00 0.98 (0.74, 1.29) 0.85 (0.65, 1.12) 1.02 (0.77, 1.34) 1.04 (0.79, 1.37) 0.69
RR4 (95% CI) 1.00 0.95 (0.71, 1.27) 0.81 (0.61, 1.09) 1.00 (0.74, 1.35) 0.98 (0.73, 1.33) 1.00
Beef
Median intake in subcohort (g/d)2 2 11 19 30 50
No. of cases 140 158 169 139 177
RR3 (95% CI) 1.00 1.13 (0.85, 1.50) 1.13 (0.85, 1.49) 1.02 (0.76, 1.37) 1.29 (0.97, 1.70) 0.10
RR4 (95% CI) 1.00 1.22 (0.90, 1.64) 1.10 (0.82, 1.49) 0.99 (0.72, 1.36) 1.23 (0.92, 1.66) 0.36
Pork
Median intake in subcohort (g/d)2 3 18 31 45 72
No. of cases 182 160 165 129 147
RR3 (95% CI) 1.00 0.96 (0.73, 1.26) 0.95 (0.73, 1.24) 0.77 (0.58, 1.02) 0.86 (0.66, 1.14) 0.04
RR4 (95% CI) 1.00 0.93 (0.70, 1.25) 0.90 (0.67, 1.20) 0.77 (0.57, 1.04) 0.80 (0.60, 1.08) 0.02
Processed meat
Median intake in subcohort (g/d)2 0 3 7 13
No. of cases 128 330 189 136
RR3 (95% CI) 1.00 0.97 (0.75, 1.25) 0.95 (0.72, 1.27) 0.98 (0.72, 1.33) 0.83
RR4 (95% CI) 1.00 0.93 (0.71, 1.23) 0.91 (0.68, 1.23) 0.93 (0.67, 1.29) 0.59
1 Reference category.
2 As raw weight.
3 Adjusted for age.
4 Adjusted for age, history of benign breast disease, maternal breast cancer, breast cancer in one or more sisters, age at menarche, age at menopause, oral
contraceptive use, parity, age at first childbirth, Quetelet index, education, alcohol use, current cigarette smoking, and energy intake.
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to the total evidence on CLA and breast cancer. No piece of evi-
dence is conclusive but must be taken in the context of all the
information available on CLA.
In the present analysis, RRs for TFAs were presented. TRANS-
FAIR data on fatty acids, used for the NLCS database, were based
on concentrations before the end of 1995, when changes in the
trans fatty acid content of manufactured consumer products, such
as margarines, led to a decrease in the intake of TFAs in the
Netherlands and other European countries. Because the follow-up
reference period ended in December 1992, this change of TFA
content will not have influenced the intakes of our subjects during
follow-up. TFAs were positively associated with breast cancer
incidence. Most prospective cohort studies addressing the relation
between fat consumption and breast cancer did not mention results
on TFAs, with the exception of a study in Seventh-day Adventists
reporting no relation (8) and the Nurses’ Health Study reporting an
inverse association with TFAs (9). Two case-control studies (5, 6)
did not find a positive association between TFA concentrations in
adipose tissue and risk of breast cancer, nor have animal studies
produced evidence for a contribution of TFAs to an elevated risk
of breast cancer. A conclusion from a review in 1996 (56) was that
there is little reason to assume that TFAs are related to risk of can-
cer in general or breast cancer in particular. An ecologic study that
examined the correlation between breast cancer incidence and
fatty acid status (as assessed in adipose tissue), however, did find
a positive association with TFAs (57). Similar data on TFA status
were also analyzed in a case-control study (7). In that study, too,
TFAs were positively associated with breast cancer risk, in par-
ticular in population groups with the lowest linoleic acid status.
A clinical study investigated whether the fatty acid composition
of adipose tissue is linked to prognoses for women diagnosed with
early-stage breast cancer (58). After an average follow-up of 7 y,
no single fatty acid appeared to be associated with survival; how-
ever, this lack of association may be attributable to the small num-
ber of deaths in that study. On the other hand, the risk of positive
lymph node findings was significantly higher for women with high
concentrations of oleic acid or saturated fatty acids and lower for
women with high TFA concentrations. None of these studies dis-
criminated among the various TFA isomers or examined whether
the TFAs were of animal or vegetable origin. One study showed
that the correlation between intake and concentration in adipose
tissue is much stronger for TFAs of vegetable than of animal ori-
gin (58).
In the present study, no association was observed between
intake of linoleic acid and breast cancer incidence. In a review and
meta-analysis, linoleic acid showed a negative association with
breast cancer in 16 case-control studies but not in cohort studies
(59). However, the results of the Nurses’ Health Study show a
significant inverse association (9). Also, no association was found
for the fish n3 PUFAs eicosapentaenoic acid and docosa-
hexaenoic acid, whereas significant positive associations with
these fatty acids originating from fish were found in the Nurses’
Health Study.
Some general remarks about the present analysis on the NLCS
have to be made. Loss to follow-up is the primary source of poten-
tial selection bias in prospective cohort studies. Given the high
completeness of follow-up of the cases and subcohort person-
years in the NLCS (34, 38) selection bias is unlikely. In prospec-
tive cohort studies, the potential problem of biased recall of past
food intake (inherent in case-control studies) is avoided because
dietary habits are reported before the disease is diagnosed.
Although not likely, symptoms of breast cancer could have
affected food consumption. However, reanalyses of data excluding
(arbitrarily) incident cases in the first 2 y of follow-up did not
change the results significantly (data not shown). The food-frequency
questionnaire used was designed to measure fat intake, among
other items. In the validation study, a correlation coefficient of
0.52 was calculated for total energy-adjusted fat intake, probably
because of the relatively narrow range of fat intake in our popu-
lation. The correlation coefficient for energy-adjusted polyunsat-
urated fat with a much wider range of intake was 0.75 (40). In
addition to a validation study, 5 annually repeated measurements
of the food-frequency questionnaire were conducted. From the
results, it was concluded that the single measurement of intake of
diet in the NLCS can characterize dietary habits for a period
of ≥ 5 y (60). Furthermore, our study population consisted of
older subjects (aged 55–69 y) who were chosen because, in gen-
eral, they show more stable dietary habits than younger individu-
als (36). A disadvantage, however, is that potential effects of diet
early in life cannot be studied. There are no reasons to assume that
there is insufficient control of confounding in our analysis. We
measured and controlled for the established risk factors of breast
cancer. Finally, in the present study, multiple comparisons were
made, which could have led to findings caused by chance. How-
ever, with 941 breast cancer cases, the power was large.
In conclusion, in this study no evidence was found for a pro-
tective effect of CLA on breast cancer incidence in post-
menopausal women, as was suggested by animal experiments. If
anything, the relation found was positive. The absence of a rela-
tion between breast cancer incidence and intake of energy or fat
was in line with current opinion. Positive associations were also
found for trans unsaturated fatty acids, saturated fatty acids, and
trans vaccenic acid. Negative associations were found for
monounsaturated and cis unsaturated fatty acids and the specific
fatty acids oleic and linolenic acid.
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